Your inbox is flooded with newsletters. Your feed is chaos. Somewhere in that noise are the insights that could transform your work—but who has time to find them?

The Deep View solves this. We read everything, analyze what matters, and deliver only the intelligence you need. No duplicate stories, no filler content, no wasted time. Just the essential AI developments that impact your industry, explained clearly and concisely.

Replace hours of scattered reading with five focused minutes. While others scramble to keep up, you'll stay ahead of developments that matter. 600,000+ professionals at top companies have already made this switch.

Join them today, for free.

New to LEVITY? Start here! Want to know more about who’s behind LEVITY? Check out this page. 🙏🏼 Not subscribed to the LEVITY podcast on Youtube yet? Do it here. 🎧 More of a listener? The podcast is also available on Spotify, Apple Podcasts and other places.

This past week I had to fight the impulse to revert to “classic” LEVITY - the era when I tried to squeeze every longevity headline on Earth into a single issue. But it’s genuinely been hard to choose, so here’s the compromise: three stories, all worthy of your attention.

First: Life Biosciences just got FDA clearance for ER-100, the (as far as I know) first-ever human trial of partial epigenetic reprogramming. Researchers will inject a therapy directly into the eyes of patients with glaucoma and optic neuropathy, attempting to turn back the biological clock on damaged retinal cells. This is the same approach David Sinclair* - Life Bio’s co-founder - used to restore vision in blind mice back in 2020.

* Last week I wrote about Elon Musk’s latest comments on aging. David Sinclair, never one to miss an opening, quickly capitalized on the moment - prompting a follow from Musk on X and casually name-dropping ER-100.

We’ve been waiting for this moment for quite some time and if you want to dig deeper I’d point you to our giant guide to partial reprogramming, as well as our podcast episodes with Yuri Deigin and Daniel Ives.

Second: A new preprint proposes that the immune system can release what is poetically called “telomere rivers”. They consist of tiny, circulating particles that supposedly carry signals of youth through the body.

Telomeres, the protective caps at the ends of chromosomes, have long been linked to aging and longevity. In this work, certain immune cells in mice package fragments of telomeric DNA into microscopic vesicles and release them into the bloodstream. These “rivers” then flow through the body, where the researchers report reduced aging markers across multiple organs.

The lifespan data is off the charts. In a small group of aged mice, treatment with these telomere rivers reportedly extended median lifespan by around 17 months - an extraordinary gain in mouse terms - with some animals surviving to nearly five years of age.

But extraordinary claims etc. The caveats are substantial: this is, again, a preprint, animal numbers are small, and effects this large demand independent replication. For now, telomere rivers remain a beautiful - and very provocative - scientific claim.

Third: The Silver Linings report. We all know aging research is woefully underfunded. Now the brilliant Raiany Romanni-Klein and her team have put numbers on exactly how insane the gap is. Their open-source economic model shows that a 1-year delay in overall biological aging - making 41 the new 40 - could add $408.4 billion yearly to U.S. GDP and save 1.72 million lives by 2050.

Meanwhile, the NIH spends 0.54% of its budget on the biology of aging. Alzheimer's research alone gets 8x more - despite lacking human-relevant results for safe drugs. The report identifies ~30 high-impact R&D areas chronically underfunded due to market failures. Many of them are familiar to LEVITY readers.

It's all presented through a beautiful new website where you can adjust the parameters and see for yourself what even modest progress would mean. Go play with it at silverlinings.bio (and/or take a look at Romanni-Klein’s Tedx talk below). Then try explaining to anyone why we're not funding this.